

LILRB1/CD85j/ILT2 Protein, Human (Biotinylated, HEK293, His-Avi)

Cat. No.:	HY-P72395
Synonyms:	LIR-1; CD85 Antigen-Like Family Member J; IILT-2; MIR-7; CD85j; ILT2; LIR1; MIR7
Species:	Human
Source:	HEK293
Accession:	D9IDM8 (G24-H458)
Gene ID:	10859
Molecular Weight:	70-90 kDa

PROPERTIES

AA Sequence

G H L P K P T L W A	E P G S V I T Q G S	P V T L R C Q G G Q	E T Q E Y R L Y R E
K K T A P W I T R I	P Q E L V K K G Q F	P I P S I T W E H A	G R Y R C Y Y G S D
T A G R S E S S D P	L E L V V T G A Y I	K P T L S A Q P S P	V V N S G G N V T L
Q C D S Q V A F D G	F I L C K E G E D E	H P Q C L N S Q P H	A R G S S R A I F S
V G P V S P S R R W	W Y R C Y A Y D S N	S P Y E W S L P S D	L L E L L V L G V S
K K P S L S V Q P G	P I V A P E E T L T	L Q C G S D A G Y N	R F V L Y K D G E R
D F L Q L A G A Q P	Q A G L S Q A N F T	L G P V S R S Y G G	Q Y R C Y G A H N L
S S E W S A P S D P	L D I L I A G Q F Y	D R V S L S V Q P G	P T V A S G E N V T
L L C Q S Q G W M Q	T F L L T K E G A A	D D P W R L R S T Y	Q S Q K Y Q A E F P
M G P V T S A H A G	T Y R C Y G S Q S S	K P Y L L T H P S D	P L E L V V S G P S
G G P S S P T T G P	T S T S G P E D Q P	L T P T G S D P Q S	G L G R H

Appearance Lyophilized powder.

Formulation Lyophilized from a 0.2 µm filtered solution of PBS, pH 7.4.

Endotoxin Level <1 EU/µg, determined by LAL method.

Reconstitution It is not recommended to reconstitute to a concentration less than 100 µg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Storage & Stability Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Shipping Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background LILRB1 binds MHC class I and also contain immunoreceptor tyrosine-based inhibitory motifs involved in the intracellular

transduction of inhibitory signaling, which establishes them as strong candidates for MHC class I-mediated suppression of phagocytosis^[1].

LILRB1 and PD1 shows nonoverlapping expression patterns across CD8+ TEM and TEMRA subsets, and blocking both pathways synergistically enhanced CD8+ T cell function. LILRB1 is highly expressed by the CD8+ TEMRA subset, which is the most potent population for BiTE molecule-induced toxicity. LILRB1-expressing CD8+ T cells infiltrate solid tumors. LILRB1 blockade increases CD8+ T cell cytolytic activity in vitro^[3].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA